Literature DB >> 27553515

Lobe-Specific Lymph Node Dissection as a Standard Procedure in Surgery for Non-Small Cell Lung Cancer: A Propensity Score Matching Study.

Hiroyuki Adachi1, Kentaro Sakamaki2, Teppei Nishii3, Taketsugu Yamamoto3, Takuya Nagashima3, Yoshihiro Ishikawa3, Kohei Ando3, Kazuki Yamanaka3, Katsuya Watanabe3, Yutaka Kumakiri3, Masahiro Tsuboi4, Takamitsu Maehara3, Haruhiko Nakayama3, Munetaka Masuda3.   

Abstract

INTRODUCTION: Systematic lymph node dissection (SND) is the standard procedure in surgical treatment for NSCLC, but the value of this approach for survival and nodal staging is still uncertain. In this study, we evaluated the potential of lobe-specific lymph node dissection (L-SND) in surgery for NSCLC by using a propensity score matching method.
METHODS: From 2005 to 2007, 565 patients with cT1a-2b N0-1 M0 NSCLC underwent lobectomy with lymph node dissection at our 10 affiliated hospitals. Patients were classified into groups that underwent nodal sampling, L-SND, and systematic dissection SND on the basis of pathological data for the number and extent of nodal resection. A total of 77 patients with insufficient pathological data were excluded from the study.
RESULTS: Overall, survival did not differ significantly among the groups (p = 0.552), but the rate of detection of pN2 in the SND group (13.1%) was significantly higher than in the nodal sampling (3.3%) and L-SND (9.0%) groups (p = 0.010). However, given the many confounding factors in the patient characteristics in each group, outcomes were reevaluated using a propensity score matching method for the L-SND and SND groups. After matching, the two groups had no significant differences in 5-year overall survival (73.5% for L-SND versus 75.3% for SND, p = 0.977) and pN2 detection (8.2% in both groups, p = 0.779).
CONCLUSIONS: These results suggest that lobe-specific lymph node dissection has the potential to be a standard procedure in surgical treatment for NSCLC.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lymph node dissection; Lymph node sampling; NSCLC; Nodal dissection; Nodal sampling

Mesh:

Year:  2016        PMID: 27553515     DOI: 10.1016/j.jtho.2016.08.127

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  31 in total

1.  Extensive thoracoscopic mediastinal lymph node dissection on the left side: how it should be done.

Authors:  David J Heineman; Mark I van Berge Henegouwen
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

2.  Locoregional recurrence after VATS surgery for NSCLC.

Authors:  Pierre-Emmanuel Falcoz; Gilbert Massard
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

3.  Long-Term Outcomes of Pulmonary Resection for Lung Cancer Patients with Chronic Kidney Disease.

Authors:  Yoko Yamamoto; Ryu Kanzaki; Takashi Kanou; Naoko Ose; Soichiro Funaki; Masato Minami; Yasushi Shintani
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

Review 4.  Selective lymph node dissection in early-stage non-small cell lung cancer.

Authors:  Han Han; Haiquan Chen
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

5.  Mediastinal lymph node dissection in surgical treatment for early stage non-small-cell lung cancer: lobe-specific or systematic?

Authors:  Hiroyuki Adachi; Takamitsu Maehara; Haruhiko Nakayama; Munetaka Masuda
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

6.  Surgery for mediastinal lymph node and early stage lung cancer: individualized practice based on clinical database.

Authors:  Yi-Ting Yen; Yau-Lin Tseng
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

7.  Risk Factors for Occult Lymph Node Metastasis in Peripheral Non-Small Cell Lung Cancer with Invasive Component Size 3 cm or Less.

Authors:  Youngkyu Moon; Si Young Choi; Jae Kil Park; Kyo Young Lee
Journal:  World J Surg       Date:  2020-05       Impact factor: 3.352

8.  Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients.

Authors:  Andrea Bille; Kaitlin M Woo; Usman Ahmad; Nabil P Rizk; David R Jones
Journal:  Eur J Cardiothorac Surg       Date:  2017-04-01       Impact factor: 4.191

9.  Selective versus systematic lymph node dissection (other than sampling) for clinical N2-negative non-small cell lung cancer: a meta-analysis of observational studies.

Authors:  Han Han; Yue Zhao; Haiquan Chen
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

10.  Can lobe-specific lymph node dissection be an alternative to systematic lymph node dissection in treating early-stage non-small cell lung cancer: a comprehensive systematic review and meta-analysis?

Authors:  Han-Yu Deng; Chang-Long Qin; Gang Li; Guha Alai; Yidan Lin; Xiao-Ming Qiu; Qinghua Zhou
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.